Physician profile
Harish Patel
NPI 1093818460
$5,068.82
in general payments reported to CMS, 2019-2025
24 companies · $509 in 2025
The $509 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $384 · 2021: $510 · 2022: $425 · 2023: $961 · 2024: $538 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.76 | 2021-2025 | |
| Ucb, INC. | $556.12 | 2019-2025 | Nayzilam, Fintepla |
| Emd Serono, INC. | $432.05 | 2019-2025 | Mavenclad |
| Amgen INC. | $427.64 | 2019-2020 | |
| Lilly USA, LLC | $396.19 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $307.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $281.49 | 2023-2024 | Nuedexta, Rexulti |
| Teva Pharmaceuticals USA, INC. | $244.90 | 2019-2025 | Austedo Xr |
| Kestra Medical Technology Services, INC. | $220.52 | 2024-2025 | Assure Wcd |
| Allergan, INC. | $181.51 | 2019-2020 | |
| Biogen, INC. | $173.60 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $167.06 | 2023-2024 | Fycompa |
| Biohaven Pharmaceutical Holding Company Ltd. | $161.38 | 2022 | |
| Boston Scientific Corporation | $147.40 | 2023 | Watchman Access System |
| Acorda Therapeutics, INC | $116.42 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $114.88 | 2020 | |
| Jazz Pharmaceuticals INC. | $112.11 | 2019 | |
| Sk Life Science, INC. | $99.47 | 2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $44.88 | 2019 | |
| Sumitomo Pharma America, INC. | $42.29 | 2023-2024 | Aptiom |
| Supernus Pharmaceuticals, INC. | $41.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.08 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $15.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.